LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Use of tocilizumab in a patient with severe COVID-19 in a Teaching Hospital in Ghana: a case report.

    Hardy, Yasmine Oladele / Hutton-Mensah, Kojo Awotwi / Amenuke, Divine Aseye Yao / Amoah-Dankwah, James

    The Pan African medical journal

    2020  Volume 37, Issue Suppl 1, Page(s) 30

    Abstract: The outbreak of coronavirus disease 2019 (COVID-19) in December 2019 has rapidly spread globally with significant negative impact on health. There is an urgent need for a drug or vaccine certified for treating and preventing COVID-19 respectively. ... ...

    Abstract The outbreak of coronavirus disease 2019 (COVID-19) in December 2019 has rapidly spread globally with significant negative impact on health. There is an urgent need for a drug or vaccine certified for treating and preventing COVID-19 respectively. Tocilizumab, an interleukin-6 monoclonal receptor antibody, has been used in some centers for mitigating the severe inflammatory response seen in patients with severe COVID-19 with encouraging results. To the best of our knowledge, reports detailing the outcomes of patients with severe COVID-19 undergoing treatment with tocilizumab are sparse in sub-Saharan Africa. We describe the clinical and laboratory profile, chest Computed Tomography (CT) scan findings and clinical outcome in a Ghanaian patient with severe COVID-19 pneumonia treated with tocilizumab. A 54-year-old hypertensive male presented with fever, productive cough, pleuritic chest pain and breathlessness. He tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by polymerase chain reaction analysis done on a nasopharyngeal swab sample. His respiratory symptoms worsened while on admission despite receiving standard of care. His C-reactive protein (CRP) was elevated to 80.59mg/L and chest CT scan findings were indicative of severe COVID-19 pneumonia. He was treated with a single 400mg dose of intravenous tocilizumab with a positive clinical outcome, rapid decline in CRP and improvement in chest CT findings. Our experience shows that tocilizumab shows great promise as drug therapy for COVID-19 pneumonia.
    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; COVID-19/diagnosis ; Ghana ; Hospitals, Teaching ; Humans ; Male ; Middle Aged ; Severity of Illness Index ; COVID-19 Drug Treatment
    Chemical Substances Antibodies, Monoclonal, Humanized ; tocilizumab (I031V2H011)
    Language English
    Publishing date 2020-10-29
    Publishing country Uganda
    Document type Case Reports ; Journal Article
    ZDB-ID 2514347-5
    ISSN 1937-8688 ; 1937-8688
    ISSN (online) 1937-8688
    ISSN 1937-8688
    DOI 10.11604/pamj.supp.2020.37.30.25851
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Determinants of post-disclosure violence among women living with HIV in sero-discordant unions in Kumasi, Ghana: a cross-sectional study.

    Hardy, Yasmine Oladele / Antwi, Prosper Kwame / Agbeno, Evans Kofi / Yifieyeh, Abiboye Cheduko / Enimil, Anthony / Afful, Benjamin Adjei

    AIDS care

    2020  Volume 33, Issue 2, Page(s) 187–191

    Abstract: Violence against women is a global challenge with negative health outcomes. Women living with HIV (WLHIV) in sero-discordant unions are at risk of violence after disclosure of their ... ...

    Abstract Violence against women is a global challenge with negative health outcomes. Women living with HIV (WLHIV) in sero-discordant unions are at risk of violence after disclosure of their status
    MeSH term(s) Adult ; Anti-HIV Agents/therapeutic use ; Cross-Sectional Studies ; Domestic Violence/statistics & numerical data ; Female ; Ghana/epidemiology ; HIV Infections/drug therapy ; HIV Infections/ethnology ; HIV Infections/psychology ; HIV Seronegativity ; Humans ; Male ; Sexual Partners/psychology ; Truth Disclosure ; Violence/psychology ; Violence/statistics & numerical data
    Chemical Substances Anti-HIV Agents
    Language English
    Publishing date 2020-02-06
    Publishing country England
    Document type Journal Article
    ZDB-ID 1012651-x
    ISSN 1360-0451 ; 0954-0121
    ISSN (online) 1360-0451
    ISSN 0954-0121
    DOI 10.1080/09540121.2020.1724256
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2799: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Clinical and laboratory profile and outcomes of hospitalized COVID-19 patients with type 2 diabetes mellitus in Ghana - A single-center study.

    Hardy, Yasmine Oladele / Libhaber, Elena / Ofori, Emmanuel / Amenuke, Divine Aseye Yao / Kontoh, Samuel Amoabeng / Dankwah, James Amoah / Larsen-Reindorf, Rita / Otu-Ansah, Caleb / Hutton-Mensah, Kojo / Dadson, Ebenezer / Adamu, Sheila / Akyerekoh, Kofi / Sarfo, Fred Stephen / Nkum, Bernard

    Endocrinology, diabetes & metabolism

    2022  Volume 6, Issue 1, Page(s) e391

    Abstract: Background: In sub-Saharan Africa and particularly in Ghana, there is scarcity of published literature specifically on the impact of DM on outcomes in COVID-19 patients. Based on the difference in genetic makeup and demographic patterns in Africans ... ...

    Abstract Background: In sub-Saharan Africa and particularly in Ghana, there is scarcity of published literature specifically on the impact of DM on outcomes in COVID-19 patients. Based on the difference in genetic makeup and demographic patterns in Africans compared to the Western world and with the rising burden of DM and other non-communicable diseases in Ghana there is a need to define the impact DM has on persons with COVID-19. This would ensure adequate risk stratification and surveillance for such patients as well as appropriate scale up of therapeutic management if needed.
    Aims: This single-center study describes the clinical and laboratory profile and outcomes of COVID-19 in-patients with type 2 diabetes mellitus (DM) in Ghana.
    Materials and methods: Retrospective analysis was undertaken of the medical records of adults with COVID-19 hospitalized at a facility in Ghana from March to October 2020. Clinical, laboratory and radiological data and outcomes were analysed. Comparisons between COVID-19 patients with DM and non-diabetics were done with an independent t-test or a Mann-Whitney test when normality was not attained. Odds ratios (95% CI) were calculated using univariate logistic regression.
    Results: Out of 175 COVID-19 patients, 64 (36.6%) had DM. Overall mean age was 55.9 ± 18.3 years; DM patients were older compared to non-diabetics (61.1 ± 12.8 vs. 53.0 ± 20.2 years, p = .049). Compared to non-diabetics, diabetics were more likely to have higher blood glucose at presentation, have hypertension, be on angiotensin 2 receptor blockers [OR, 95% CI 3.3 (1.6-6.7)] and angiotensin converting enzyme inhibitors [OR, 95% CI 3.1 (1.3-7.4)]; and be HIV negative (p < .05). Although the values were normal, diabetics had a higher platelet count but decreased lymphocytes, aspartate transaminase and alkaline phosphatase compared to non-diabetics (p < .05). There was no difference in clinical symptoms, severity or mortality between the two groups.
    Discussion: The clinical profile of patients studied are similar to prior studies. However the outcome of this study showed that DM was not associated with worse clinical severity and in-hospital mortality. This could have been due to majority of DM patients in this study having relatively good blood glucose control on admission. Secondly, DM alone may not be a risk factor for mortality. Rather its concurrent existence with multiple co-morbidities (especially cardiovascular co-morbidities which may predispose to pro-inflammatory and pro-thrombotic states) may be driving the rise in severity and mortality risks reported in other studies. Furthermore, this study was conducted among an African population and Africa has been shown to be generally less severely hit by the COVID-19 pandemic compared to other regions outside the continent. This has been postulated to be due, among other factors, to inherent protective mechanisms in Africans due to early and repeated exposure to parasitic and other organisms resulting in a robust innate immunity.
    Conclusions: This study suggested that DM was not associated with more severe clinical symptoms or worse outcomes among hospitalized COVID-19 patients. Despite this, it is important that DM patients adhere to their therapy, observe the COVID-19 containment protocols and are prioritized in the administration of the COVID-19 vaccines.
    Study highlights: In this retrospective, single-centre study on the clinical and laboratory profile and outcome of hospitalized DM patients with COVID-19, patients with DM did not have a more severe clinical profile or worse outcomes. They were, however, significantly older, more likely to have higher admission blood glucose, have hypertension, be on angiotensin 2 receptor blockers and angiotensin converting enzyme inhibitors; and be HIV negative compared to the cohort without DM. DM patients should be a priority group for the COVID-19 vaccines.
    MeSH term(s) Adult ; Humans ; Middle Aged ; Aged ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/epidemiology ; COVID-19/complications ; COVID-19/epidemiology ; Retrospective Studies ; Blood Glucose ; COVID-19 Vaccines ; Ghana/epidemiology ; Pandemics ; Hypertension/epidemiology ; Hypertension/etiology ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Angiotensins ; HIV Infections
    Chemical Substances Blood Glucose ; COVID-19 Vaccines ; Angiotensin-Converting Enzyme Inhibitors ; Angiotensins
    Language English
    Publishing date 2022-11-25
    Publishing country England
    Document type Journal Article
    ISSN 2398-9238
    ISSN (online) 2398-9238
    DOI 10.1002/edm2.391
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top